Nathan I Nicely

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2406546/publications.pdf

Version: 2024-02-01

21	1,534	623734	752698
papers	citations	14 h-index	20 g-index

22	22	22	2333
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines. Journal of Biological Chemistry, 2022, 298, 102079.	3.4	2
2	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57
3	Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. Science Advances, 2021, 7, eabg4084.	10.3	22
4	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35
5	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. PLoS Pathogens, 2019, 15, e1008165.	4.7	5
6	Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. Retrovirology, 2018, 15, 24.	2.0	0
7	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. Journal of Immunology, 2017, 198, 1047-1055.	0.8	7
8	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. Journal of Virology, 2017, 91, .	3.4	73
9	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
10	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
11	A Novel Phosphoregulatory Switch Controls the Activity and Function of the Major Catalytic Subunit of Protein Kinase A in Aspergillus fumigatus. MBio, 2017, 8, .	4.1	9
12	Phosphorylation of Aspergillus fumigatus PkaR impacts growth and cell wall integrity through novel mechanisms. FEBS Letters, 2017, 591, 3730-3744.	2.8	5
13	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
14	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
15	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
16	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	6.1	13
17	Polyreactivity and Autoreactivity among HIV-1 Antibodies. Journal of Virology, 2015, 89, 784-798.	3.4	154
18	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65

#	Article	IF	Citations
19	Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. Journal of Experimental Medicine, 2013, 210, 241-256.	8.5	171
20	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
21	Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nature Structural and Molecular Biology, 2010, 17, 1492-1494.	8.2	43